Lineage Cell Therapeutics Inc. Overview

Lineage Cell Therapeutics, Inc., a biotechnology company based in Carlsbad, is making strides in the health care sector with its focus on cell-based therapies and gene marker-based molecular diagnostics. The company operates across the United States, targeting various diseases and degenerative conditions.

Financial Snapshot

As of June 15, 2025, Lineage Cell Therapeutics Inc. is listed on the NYSE American with a close price of $0.86. The company’s stock has experienced significant volatility over the past year, reaching a 52-week high of $1.15 on July 22, 2024, and a low of $0.37 on April 8, 2025. The market capitalization stands at approximately $160.42 million.

Performance Metrics

The company’s price-to-earnings ratio is currently at -8.63, reflecting its financial performance and market expectations. This metric indicates that the company is not yet profitable, which is not uncommon for companies in the biotechnology sector that are heavily invested in research and development.

Industry Focus

Lineage Cell Therapeutics is dedicated to advancing cell-based therapies and developing molecular diagnostics that utilize gene markers. These innovative approaches aim to address a wide range of diseases and degenerative conditions, positioning the company as a key player in the biotechnology industry.

Conclusion

Despite the challenges reflected in its financial metrics, Lineage Cell Therapeutics Inc. continues to focus on its core mission of developing cutting-edge therapies and diagnostics. The company’s efforts in the biotechnology sector highlight its commitment to addressing critical health issues through innovative solutions.